

Press release 2019-02-06

Quickcool AB: first day of trading of TO2 is February 14, 2019

Clarification; the first day of trading with TO2 is 14 February, 2019.

Notification of subscription of shares on the basis of warrants may take place during the following dates:

2019

18 February – 1 March 2019
20 May 2019 – 31 May 2019
19 August – 30 August 2019
18 November 2019 – 29 November 2019

2020

17 February – 28 February 2020
 18 May 2020 – 29 May 2020
 17 August – 28 August 2020
 16 November 2020 – 30 November 2020

2021

15 February – 1 March 2021
17 May 2021 – 31 May 2021
16 August – 30 August 2021
15 November 2021 – 30 November 2021

In the case of such notification, for registration purposes, a completed application form shall be submitted to the calculation manager or to another institution that can forward the same. Notice of subscription is binding and cannot be revoked by the subscriber. In the case of notification of subscription, payment shall be made at once for the number of shares to which the notification of subscription is related. After allotment, subscription is effected by the inclusion of the new shares in the company's share register as interim shares. After registration at the Swedish Companies Registration Office has taken place, the registration on the CSD account is final.

For additional information, please contact: Fredrik Radencrantz, CEO Phone: 046-286 38 40 E-mail: <u>fredrik.radencrantz@quickcool.se</u>

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of

QuickCool AB (publ) Ideon Science Park • Scheelevägen 17 SE-223 70 Lund • Sweden



 Phone
 +46 (0)46 286 38 40

 Email
 contact@quickcool.se

 Web:
 www.quickcool.se

 Org Nr
 556639-3913



patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to <u>www.quickcool.se</u>



 Phone
 +46 (0)46 286 38 40

 Email
 contact@quickcool.se

 Web:
 www.quickcool.se

 Org Nr
 556639-3913